tirzepatide and hyperthyroidism PDF) Association Between Therapy Thyroid Function in Euthyroid Patients With Obesity Tirzepatide & Thyroid Issues: Safety,

Repova K, Baka T, Krajcirovicova K, Stanko P, Aziriova S, Reiter RJ, Simko F

doi: 10.1097/MED.0000000000000074

In the central nervous system, GLP-1 RAs regulate response to food cues and decrease food intake

Clinical Implications The STEP-HFpEF trial program, which includes STEP-HFpEF (in patients with HFpEF and obesity) and STEP-HFpEF DM (in patients with HFpEF, obesity, and T2DM) demonstrated significant benefits of weekly subcutaneous semaglutide 2.4 mg, improving physical function, alleviating symptoms, and promoting weight loss with potential disease-modifying effects.(12,13) The dual primary endpoints of change in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS ) and percentage weight loss at 52 weeks drove the positive results of the trials